Advertisement

Topics

Companies Related to "Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer" [Most Relevant Company Matches] RSS

04:03 EDT 22nd May 2018 | BioPortfolio

Here are the most relevant search results for "Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Chemosensitivity Testing Assign Treatment Patients With Stage Stage" Companies 1–25 of 7,600+

Extremely Relevant

HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In thi...


Relevant

HealthCare Pharmaceuticals, Inc.

HealthCare Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel, targeted therapies for the treatment of patients with cancer. DKN-01, our clinical-stage monoclonal antibody, is currently being tested in Phase 1b and Phase 2 clinical trials for patients with DKK1+ esophageal cancer and multiple mye...

Aurinia Pharmaceuticals Inc.

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (“LN”). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal d...


Salix Pharmaceuticals

Salix Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to gastroenterologists and their patients. In-license selective late-stage/marketed products Our "search and development" efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an...

Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those ...

EUSA Pharma Inc

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinas...

Cancer Treatment Centers of America, Inc.

Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Stand...

EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol(R) for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinas...

Okuvision GmbH

Founded by the leaders of Retina Implant AG in 2007, Okuvision GmbH is an innovator in the field of electrical stimulation therapy (EST) for patients with early and intermediate stage retinitis pigmentosa. Building on the lessons learned through the use of Retina Implant’s subretinal implant technology, Okuvision was founded with the goal of testing a...

SanBio, Inc.

SanBio is a regenerative medicine company with cell based products in various stages of research, development and clinical trials. Its proprietary cell based product, SB623, is beginning Stage 2b clinical trials for treatment of chronic stroke. SanBio also began Stage 2 clinical trials for treatment of traumatic brain injury in 2015. More information about...

Cerevance

Cerevance is a recently formed pharmaceutical company focused on central nervous system diseases. The company’s strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. Its scientists believe that they are well positioned to deliver life-changing therapeutics for ...

Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a commercial-stage biopharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA® (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE® (gemifloxacin mesylate) tablets is...

Cancer Treatment Centers of America (CTCA)

Cancer Treatment Centers of America (CTCA) is a growing network of regional destination hospitals specializing in complex and advance-stage cancer care. CTCA provides a comprehensive, fully integrated and individualized cancer treatment experience at regional hospitals located in Chicago, Philadelphia, Phoenix and Tulsa. The Patient Empowered Care® mode...

Propel Technology

PROPEL is a group of programs aimed at increasing the number and success rate of early-stage life sciences companies in Illinois. PROPEL helps guide the development of formation-stage and early-stage life sciences companies by providing entrepreneurs with access to specialized resources and expertise to prepare them for early-stage funding. PROPEL is a Cen...

SciFluor Life Sciences, LLC

SciFluor Life Sciences is an Allied Minds-funded company with a late-stage fluorination technology that improves drug properties such as metabolic stability, potency, bioavailability, and blood-brain barrier penetration. The company's late-stage fluorination technology, and its companion portfolio of fluorinated pharmaceuticals, are licensed exclusively fr...

Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop an...

Sinexus, Inc.

Sinexus, Inc. (http://www.sinexusinc.com) is a development-stage medical device company that is pioneering novel therapies for Ear, Nose & Throat (ENT) physicians to utilize in providing improved treatment for their patients. Sinexus' initial focus is treating patients with Chronic Rhinosinusitis, a debilitating chronic condition that affects one out of seven adults in the United States.

Jennerex Biotherapeutics, Inc.

Jennerex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of groundbreaking oncolytic immunotherapies for patients with life-threatening cancers. The company’s lead product candidate, Pexa-Vec (JX-594), is in mid-stage clinical development for the treatment of advanced primary liver cancer, ...

Cancer Treatment Centers of America and Cigna

CTCA is a growing network of regional destination hospitals specializing in complex and advance-stage cancer care. CTCA provides a comprehensive, fully integrated and individualized cancer treatment experience at hospitals located in suburban Chicago, Philadelphia, suburban Phoenix and Tulsa, with a fifth hospital opening in Atlanta in the summer of 2012. ...

CellControl Biomedical Laboratories GmbH

CellControl is a R&D service company for pharmaceutical companies and clinical research institutions. CellControl also offers cancer patients a chemosensitivity-test.

Lux Biosciences, Inc.

Lux Biosciences, Inc. is a privately held biotechnology company focused on the treatment of ophthalmic diseases. Lux Biosciences has exclusive worldwide rights to voclosporin for all ophthalmic indications and is cooperating with the team at Isotechnika Pharma who discovered the molecule. For more information on Lux Biosciences, please visit the companyâ...

Stage Front Presentation Systems

Established in 1978, Stage Front designs and deploys high-impact technical systems that help people educate, communicate, and entertain. For institutions of higher learning, Stage Front equips teaching spaces to deliver curriculum via a variety of electronic sources including computer, broadband television, DVD, document camera, electronic whiteboard, micr...

Zelos Therapeutics Inc.

Zelos Therapeutics is an emerging private biopharmaceutical development company that is commercializing breakthrough discoveries in parathyroid hormone (PTH) research. The company is developing medications for the treatment of osteoporosis, psoriasis and for enhancing engraftment following stem cell transplantation. During 2005, Zelos Therapeutics experienced a number of significant milestones. Ke...

Harbor BioSciences, Inc.

Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone (HE3235), in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform bas...

Grid Therapeutics, LLC

Grid Therapeutics is a biotech company based on the innovative platform for discovering and isolating human derived antibodies. Dr Edward F. Patz, Jr, is the co-founder and CEO of Grid, located in Durham, North Carolina. The lead antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. ...


More From BioPortfolio on "Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks